2024
Menopausal hormone therapy: assessing associations with breast and colorectal cancers by familial risk
Macinnis R, Jenkins M, Milne R, John E, Daly M, Andrulis I, Colonna S, Phillips K, Investigators K, Le Marchand L, Newcomb P, Phipps A, Schmit S, Macrae F, Buchanan D, Gallinger S, Pai R, Samadder N, Giles G, Southey M, Hopper J, Terry M. Menopausal hormone therapy: assessing associations with breast and colorectal cancers by familial risk. JNCI Cancer Spectrum 2024, pkae121. PMID: 39673461, DOI: 10.1093/jncics/pkae121.Peer-Reviewed Original ResearchFamily risk scoreMenopausal hormone therapyFamilial riskHazard ratioColorectal cancerFamilial risk of BCBreast cancerFamily historyDecreased colorectal cancerCancer family historyRisk of BCIncreased breast cancerAssociated with breastIncident BCNever usersGeneral populationRisk scoreHarmonized dataWomenHormone therapyRiskAssociationCancerNeverCohortChildhood physical activity and pubertal timing: findings from the LEGACY girls study
Kehm R, Knight J, Houghton L, McDonald J, Schwartz L, Goldberg M, Chung W, Frost C, Wei Y, Bradbury A, Keegan T, Daly M, Buys S, Andrulis I, John E, Terry M. Childhood physical activity and pubertal timing: findings from the LEGACY girls study. International Journal Of Epidemiology 2024, 53: dyad193. PMID: 38205889, PMCID: PMC10859159, DOI: 10.1093/ije/dyad193.Peer-Reviewed Original ResearchConceptsBreast cancer family historyBody mass index-for-age z-scorePhysical activityChildhood physical activityCancer family historyLEGACY Girls StudyAssociated with later menarcheParametric survival regression modelsOrganized PAMetabolic equivalentsInverse oddsEarly childhoodSociodemographic factorsEffect modificationAssociated with ageLater menarcheNorth American cohortFamily historySurvival regression modelsStudy enrollmentMiddle childhoodAmerican cohortQuestionnaire dataPotential mediatorsZ-score
2020
Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk
Kramer I, Hooning M, Mavaddat N, Hauptmann M, Keeman R, Steyerberg E, Giardiello D, Antoniou A, Pharoah P, Canisius S, Abu-Ful Z, Andrulis I, Anton-Culver H, Aronson K, Augustinsson A, Becher H, Beckmann M, Behrens S, Benitez J, Bermisheva M, Bogdanova N, Bojesen S, Bolla M, Bonanni B, Brauch H, Bremer M, Brucker S, Burwinkel B, Castelao J, Chan T, Chang-Claude J, Chanock S, Chenevix-Trench G, Choi J, Clarke C, Collée J, Couch F, Cox A, Cross S, Czene K, Daly M, Devilee P, Dörk T, dos-Santos-Silva I, Dunning A, Dwek M, Eccles D, Evans D, Fasching P, Flyger H, Gago-Dominguez M, García-Closas M, García-Sáenz J, Giles G, Goldgar D, González-Neira A, Haiman C, Håkansson N, Hamann U, Hartman M, Heemskerk-Gerritsen B, Hollestelle A, Hopper J, Hou M, Howell A, Ito H, Jakimovska M, Jakubowska A, Janni W, John E, Jung A, Kang D, Kets C, Khusnutdinova E, Ko Y, Kristensen V, Kurian A, Kwong A, Lambrechts D, Le Marchand L, Li J, Lindblom A, Lubiński J, Mannermaa A, Manoochehri M, Margolin S, Matsuo K, Mavroudis D, Meindl A, Milne R, Mulligan A, Muranen T, Neuhausen S, Nevanlinna H, Newman W, Olshan A, Olson J, Olsson H, Park-Simon T, Peto J, Petridis C, Plaseska-Karanfilska D, Presneau N, Pylkäs K, Radice P, Rennert G, Romero A, Roylance R, Saloustros E, Sawyer E, Schmutzler R, Schwentner L, Scott R, See M, Shah M, Shen C, Shu X, Siesling S, Slager S, Sohn C, Southey M, Spinelli J, Stone J, Tapper W, Tengström M, Teo S, Terry M, Tollenaar R, Tomlinson I, Troester M, Vachon C, van Ongeval C, van Veen E, Winqvist R, Wolk A, Zheng W, Ziogas A, Easton D, Hall P, Schmidt M, Børresen-Dale A, Sahlberg K, Ottestad L, Kåresen R, Schlichting E, Holmen M, Sauer T, Haakensen V, Engebråten O, Naume B, Fosså A, Kiserud C, Reinertsen K, Helland Å, Riis M, Geisler J, Alnæs G, Clarke C, Marsh D, Scott C, Baxter R, Yip D, Carpenter J, Davis A, Pathmanathan N, Simpson P, Graham J, Sachchithananthan M, Amor D, Andrews L, Antill Y, Balleine R, Beesley J, Bennett I, Bogwitz M, Botes L, Brennan M, Brown M, Buckley M, Burke J, Butow P, Caldon L, Campbell I, Chauhan D, Chauhan M, Chenevix-Trench G, Christian A, Cohen P, Colley A, Crook A, Cui J, Cummings M, Dawson S, deFazio A, Delatycki M, Dickson R, Dixon J, Edkins T, Edwards S, Farshid G, Fellows A, Fenton G, Field M, Flanagan J, Fong P, Forrest L, Fox S, French J, Friedlander M, Gaff C, Gattas M, George P, Greening S, Harris M, Hart S, Hayward N, Hopper J, Hoskins C, Hunt C, James P, Jenkins M, Kidd A, Kirk J, Koehler J, Kollias J, Lakhani S, Lawrence M, Lindeman G, Lipton L, Lobb L, Mann G, Marsh D, McLachlan S, Meiser B, Milne R, Nightingale S, O'Connell S, O'Sullivan S, Ortega D, Pachter N, Patterson B, Pearn A, Phillips K, Pieper E, Rickard E, Robinson B, Saleh M, Salisbury E, Saunders C, Saunus J, Scott C, Scott C, Sexton A, Shelling A, Simpson P, Southey M, Spurdle A, Taylor J, Taylor R, Thorne H, Trainer A, Tucker K, Visvader J, Walker L, Williams R, Winship I, Young M. Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. American Journal Of Human Genetics 2020, 107: 837-848. PMID: 33022221, PMCID: PMC7675034, DOI: 10.1016/j.ajhg.2020.09.001.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAsian PeopleBreast NeoplasmsCohort StudiesEstrogen Receptor alphaFemaleGene ExpressionGenetic Predisposition to DiseaseGenome-Wide Association StudyGenome, HumanHumansMiddle AgedMultifactorial InheritanceNeoadjuvant TherapyNeoplasms, Second PrimaryPrognosisProportional Hazards ModelsReceptor, ErbB-2Receptors, ProgesteroneRisk AssessmentWhite PeopleConceptsContralateral breast cancerPolygenic risk scoresInvasive breast cancerCBC risk prediction modelAssociated with increased CBC riskRisk of contralateral breast cancerBreast Cancer Association ConsortiumBreast cancerWomen of European ancestryStudies of Asian womenAbsolute lifetime riskUnilateral breast cancerEvidence of confoundingRisk prediction modelFollow-upStratify womenEuropean ancestryFamily historyHazard ratioRisk scoreLogistic regressionAsian womenEuropean womenGermline variantsOptimal surveillanceImplementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.
Giri VN, Knudsen KE, Kelly WK, Cheng HH, Cooney KA, Cookson MS, Dahut W, Weissman S, Soule HR, Petrylak DP, Dicker AP, AlDubayan SH, Toland AE, Pritchard CC, Pettaway CA, Daly MB, Mohler JL, Parsons JK, Carroll PR, Pilarski R, Blanco A, Woodson A, Rahm A, Taplin ME, Polascik TJ, Helfand BT, Hyatt C, Morgans AK, Feng F, Mullane M, Powers J, Concepcion R, Lin DW, Wender R, Mark JR, Costello A, Burnett AL, Sartor O, Isaacs WB, Xu J, Weitzel J, Andriole GL, Beltran H, Briganti A, Byrne L, Calvaresi A, Chandrasekar T, Chen DYT, Den RB, Dobi A, Crawford ED, Eastham J, Eggener S, Freedman ML, Garnick M, Gomella PT, Handley N, Hurwitz MD, Izes J, Karnes RJ, Lallas C, Languino L, Loeb S, Lopez AM, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann M, Mille P, Miner MM, Morgan T, Moreno J, Mucci L, Myers RE, Nielsen SM, O'Neil B, Pinover W, Pinto P, Poage W, Raj GV, Rebbeck TR, Ryan C, Sandler H, Schiewer M, Scott EMD, Szymaniak B, Tester W, Trabulsi EJ, Vapiwala N, Yu EY, Zeigler-Johnson C, Gomella LG. Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. Journal Of Clinical Oncology 2020, 38: 2798-2811. PMID: 32516092, PMCID: PMC7430215, DOI: 10.1200/jco.20.00046.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsGermline testingFamily historyAdditional family historyHereditary cancer assessmentMetastatic disease treatmentAge 40 yearsClinical trial eligibilityPost-test discussionMultidisciplinary consensus conferenceProstate cancer treatmentMismatch repair genesCurrent practice challengesHereditary PCaTrial eligibilityMetastatic diseasePriority genesPathologic criteriaSomatic testingMetastatic PCaProstate cancerPCa diagnosisConsensus conferenceEvidence reviewCancer assessmentInformed consent
2010
Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2
Petrucelli N, Daly M, Feldman G. Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2. Genetics In Medicine 2010, 12: 245-259. PMID: 20216074, DOI: 10.1097/gim.0b013e3181d38f2f.Peer-Reviewed Original ResearchConceptsBRCA1/2 mutationsBRCA2 mutationsHereditary breastTesting of at-risk relativesFamily history of cancerOvarian cancerAt-risk relativesPrimary prevention optionsHistory of cancerPrevalence of BRCA1/2 mutationsEstimates of penetranceAshkenazi Jewish populationCancer riskProphylactic surgeryPrevention optionsFamily historyBRCA2 genesEarly interventionFamily membersBRCA2Increased surveillanceFamilial mutationsBRCA1/2BRCA1Jewish population
2006
BRCA1 and BRCA2 Mutation Carriers, Oral Contraceptive Use, and Breast Cancer Before Age 50
Haile R, Thomas D, McGuire V, Felberg A, John E, Milne R, Hopper J, Jenkins M, Levine A, Daly M, Buys S, Senie R, Andrulis I, Knight J, Godwin A, Southey M, McCredie M, Giles G, Andrews L, Tucker K, Miron A, Apicella C, Tesoriero A, Bane A, Pike M, Whittemore A, Investigators K. BRCA1 and BRCA2 Mutation Carriers, Oral Contraceptive Use, and Breast Cancer Before Age 50. Cancer Epidemiology Biomarkers & Prevention 2006, 15: 1863-1870. PMID: 17021353, DOI: 10.1158/1055-9965.epi-06-0258.Peer-Reviewed Original ResearchMeSH KeywordsAdultAustraliaBreast NeoplasmsCanadaCarcinoma in SituCarcinoma, Ductal, BreastCase-Control StudiesContraceptives, OralFemaleGenes, BRCA1Genes, BRCA2Genetic Predisposition to DiseaseHeterozygoteHumansLogistic ModelsMiddle AgedMutationReceptors, EstrogenReceptors, ProgesteroneRisk FactorsSurveys and QuestionnairesTime FactorsUnited StatesConceptsRisk of breast cancerBRCA2 mutation carriersOral contraceptive useMutation carriersAssociated with breast cancer riskIncreased risk of breast cancerBreast cancerOral contraceptivesContraceptive useBreast cancer riskUnconditional logistic regressionDuration of oral contraceptive useBRCA1 mutation carriersDuration of useCase-control analysisEffects of oral contraceptivesCancer riskFamily historyModify practicesElevated riskLogistic regressionIncreased riskBRCA2Family relationshipsBRCA1
1998
Epidemiology and risk assessment for ovarian cancer.
Daly M, Obrams G. Epidemiology and risk assessment for ovarian cancer. Seminars In Oncology 1998, 25: 255-64. PMID: 9633839.Peer-Reviewed Original ResearchConceptsIncidence of ovarian cancerOral contraceptive useOvarian cancerAssociated with increased ovarian cancer riskIncidence rate of ovarian cancerContraceptive useRisk of ovarian cancerRate of ovarian cancerOvarian cancer riskAsian American womenNative American womenPregnancy historyHawaiian womenFamily historyCancer riskWoman's riskRisk factorsIncidence rateAmerican womenCancerAfrican AmericansWomenCosmetic talcIncidenceUnited States